Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Laurent, thanks for tracking the panel. I hope today's "marjac" rally is due to a leak that Judges Newman and Moore will preside over marjac's case tomorrow morning.
Not by choice but by necessity. Judge Du must be patting her own back.
" in the absence of patent protection innovation dies."? Sadly, only Judge Newman and Moore recognize that. Amarin is not BP but is still a greedy pharma company, just ask Judge Du, Prost, Huges ...
Laurent, among Judges Dyk,Prost,Hughes,Newman,Stoll,Moore,Reyna,and Cunningham, which Judge did not sit for even 1 case last three days?
Laurent, thanks for tracking. Was Judge Newman on a Tueday's panel. I didn't see her name on Monday or Wednesday and I forgot to check Tuesday's panel makeup. TIA.
marjac, you are right with your argument. However, I would not underestimate some judges' disdain towards greedy pharma companies (i.e. Amarin) and their high regard towards generic companies (i.e., Hikma/Dr. Reddy's) for their roles in saving our healthcare system (which we know is not true). To the panel, GV is just as effective as V but cheaper.
Thanks for all you have done which can't be expressed by words alone. Therefore, I'll pick up the tab in your favorite restaurant at Great Neck, NY, for our victory celebration.
The problem is the verdict won't out from the court case tomorrow.
New low?
xbl, "caused Amarin to stop advertising and gut its sales force!!"? Please don't mention it, otherwise, the panel would blame Amarin for stopping advertising and gutting its workforce and causing more CVD death. To the panel, GV is just as effective as V but cheaper.
could, Marjac shouldn't bring up CVD or covid burden at the hearing. To the judges, GV is just as good as V but cheaper. There is not enough time for Marjac to explain to the judges the difference between GV and V at the hearing and even if there were enough time, there was no definite proof that GV is worst than V to show it to the panel.
Did any posters see Judge Newman's name on any of the CAFC cases last three days? I only see Judge Moore's name on Monday's cases and I forgot to check yesterday's CAFC panel names.
Posted by biobillionaire?
"Gross margin may go down"? I believe gross margin can be maintained by modulating the current rebate card program. I am willing to pay more than $9 for 3-month supply of V.
There is no reason for insurance companies to provide coverage for GV as GL is a cheaper and more efficacious drug for TG>500.
Kiwi, V sounds like a steal, cost $3000/yr with RRR of 26% Vs $4500-$6000/yr for PCSK9 injectibles with RRR of only 15% while Inclirisan doesn't even have outcome data yet. Only in medicine with greedy insurance companies and uninformed doctors that cheaper, more efficacious, and convenient drugs that couldn't outsell more expensive, less effective, and more difficult to use alternatives. I couldn't think of a similar situation in another industry.
Amarin price target lowered to $11 from $12 at SVB Leerink:
SVB Leerink analyst Roanna Ruiz lowered the firm's price target on Amarin to $11 from $12 and keeps an Outperform rating on the shares ahead of the company's Q4 results. Consensus estimate have been slow to reach Amarin's preannounced numbers in early January, which could put minor pressure on the stock in the near term, Ruiz tells investors in a research note. The analyst continues to think both the company's Europe opportunity and pre-announced fiscal 202 total revenues of $580M are underappreciated by investors.
Pfizer (PFE), Ionis (IONS) announce discontinuation of vupanorsen clinical development program:
"the study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C), as well as statistically significant reductions in triglycerides (TG) and angiopoietin-like 3 (ANGPTL3). However, the magnitude of non-HDL-C and TG reduction observed did not support continuation of the clinical development program for CV risk reduction or SHTG. Vupanorsen was also associated with dose-dependent increases in liver fat, and higher doses were associated with elevations in the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST)."
https://www.streetinsider.com/Corporate+News/Pfizer+%28PFE%29%2C+Ionis+%28IONS%29+announce+discontinuation+of+vupanorsen+clinical+development+program/19527593.html
I think PFE has already found its drug target for CV risk reduction or SHTG.
That depends on Icahn and Denner's relationship after their split. I think more hedge funds will get involved with AMRN as Lampert's BVF has already initiated a big position as of the last 13D filing. Did lizzy and LBL say BVF has further increased its AMRN positions recently since the last filing?
liz, just saw your post. north is correct about the barron's mention on p.41:
Original Filings
Amarin (AMRN) Sarissa Capital Management
reported a fresh stake in the cardiovascular- focused biopharmaceutical of 24 million American depositary receipts, or 6.6% of the outstanding shares. That amount includes 7.15 million Amarin ADRs bought from Nov. 26, 2021, through Jan. 24, 2022, at per share prices ranging from $2.93 to $3.69. No reason was given for the investment other than that Sarissa viewed Dublin-based Amarin as “significantly undervalued.”
Kiwi, combined V+GV+GL scripts per year is over $1B in US revenue. That's with piss poor Amarin marketing. With NVS marketing experience and reach, it could easily double the script numbers in EU in a relatively short time since there are no GL and GV competitions in EU.
"Icahn's chief scout is Alex Denner, who has a Ph.D. in biomedical engineering, a thick Boston accent and a decade of experience watching Genzyme (the firm had owned a 1% stake in 2007). Denner saw the company as part beauty, part beast."
https://www.forbes.com/forbes/2011/0328/billionaires-11-profile-carl-icahn-biotech-twa-raiders-radar.html?sh=798bd947edde
iryo, thanks for your continued contribution to this board. Did PREPARE-IT 2 still went ahead and presented last November despite its non-statistically significant result?
Did you forget MLK holiday discount?
Denner just join us, now JL's back, Buffet next?
In 2016, ARIAD Announced Election of Alex Denner as Chairman of the Board of Directors:
https://www.businesswire.com/news/home/20160110005030/en/ARIAD-Announces-Election-of-Alex-Denner-as-Chairman-of-the-Board-of-Directors
In 2017, Takeda acquired ARIAD Pharmaceuticals, Inc.
https://www.takeda.com/newsroom/newsreleases/2017/Takeda-to-Acquire-ARIAD-Pharmaceuticals-Inc/
Ns, that's how the trial is being titled in ClinicalTrials.gov:
https://clinicaltrials.gov/ct2/show/NCT04505098
liz, so based on different contacts, LBL's and yours, BVF has also increased its AMRN holdings from last quarter, is that correct? TIA.
IBB down 1.3% while AMRN up 10%. Thank you Dr. Denner! IHUB AMRN board memebers owe you big time.
Sarissa's Alex Denner:
I believe Dr. Denner owns as many AMRN shares as IHUB board members in total.
Hallelujah!
8100 patents worldwide and 3146 patients in US for R-I trial.
kiwi, my point is lowering LDL-C further with zetia would only provide a patient with RRR of 6.7% while lowering TG further with Vascepa would provide a patient with RRR of 25%. Vascepa should be the first statin add-on drug, not zetia or PCSK9. Unfortunately, doctors have failed their patients. That's why CVD is still the #1 killer.
Kiwi, IMPROVE-IT's RRR is 6.7% Vs REDUCE-IT's 25%, only doctors who don't know or don't care would prescribe Zetia. Patients would definitely go for 4 times the efficacy if they knew.
Kiwi, "class 1 but only level B"? Is it USA or EU only or both? Do you have a link? TIA.
The better question is why doctors continue to prescribe GL off-label despite the fact that GL increases LDL-C and causes afib. Do doctors go to medical school to get stupid or they are just too lazy to read the drug label?
"on the short week"? Not true.
Not true, V beat GL in % increase, for a change.
marjac, not only did the CAFC take your case for oral argument, it also squeezes in your case as the last possible one for the month of February so that we wouldn't have to ponder for an additional few months.
KM's great presentation @ JPMHC seems to have changed the price action of AMRN to the bullish side.